title: Plasma insulin-like growth factors and bone formation in uremic hyperparathyroidism.
abstract: Bone formation in uremia is considered to be regulated in part by parathyroid hormone (PTH). However, while low levels of immunoreactive PTH are usually associated with low rates of bone formation in uremia, elevated PTH levels do not always correlate with increased bone formation. In an attempt to identify other factors that may regulate bone formation in uremic patients, we measured plasma immunoreactive insulin-like growth factors (IGF-I and IGF-II) in 15 patients who did not have aluminum-associated reductions in bone formation. Plasma levels of IGF-I but not PTH, were significantly higher in patients with high rates of bone formation when compared to patients with low or normal bone formation (P less than 0.02). While the bone formation rate at the tissue level correlated significantly with plasma PTH (r = 0.53, P less than 0.05) and IGF-I (r = 0.67, P less than 0.01), only for plasma IGF-I were there significant correlations with bone apposition (r = 0.57, P less than 0.05) and bone formation rate at the BMU level (r = 0.62, P less than 0.02), parameters which reflect mineralization activity at the cellular level. Among the static histologic parameters, osteoblastic osteoid correlated only with plasma PTH (r = 0.76, P less than 0.001), while osteoclast number correlated with both PTH (r = 0.56, P less than 0.05) and IGF-I (r = 0.67, P less than 0.01). There were no correlations between IGF-II levels and bone histology. From these data we suggest that IGF-I may promote bone formation in uremic patients with hyperparathyroidism.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Division of Nephrology, Veterans Administration Medical Center, Seattle, Washington.
authors.forename: D L
authors.initials: DL
authors.lastname: Andress
authors.forename: M R
authors.initials: MR
authors.lastname: Pandian
authors.forename: D B
authors.initials: DB
authors.lastname: Endres
authors.forename: J B
authors.initials: JB
authors.lastname: Kopp
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D006961:Hyperparathyroidism / Q000097:blood* / Q000150:complications / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010012:Osteogenesis; D010281:Parathyroid Hormone / Q000097:blood; D013002:Somatomedins / Q000378:metabolism*; D014511:Uremia / Q000097:blood* / Q000150:complications / Q000473:pathology
chemical_list: D010281:Parathyroid Hormone; D013002:Somatomedins